Vaxcyte (NASDAQ:PCVX) COO Sells 2,250 Shares of Stock

Vaxcyte, Inc. (NASDAQ:PCVX) COO Jim Wassil sold 2,250 shares of the business’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $56.33, for a total transaction of $126,742.50. Following the transaction, the chief operating officer directly owned 156,760 shares of the company’s stock, valued at approximately $8,830,290.80. This represents a 1.42% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jim Wassil also recently made the following trade(s):

• On Monday, June 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The shares were sold at an average price of $49.52, for a total transaction of $111,420.00.
• On Friday, May 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The stock was sold at an average price of $56.83, for a total value of $127,867.50.

Vaxcyte Price Performance

Shares of NASDAQ PCVX traded down $1.43 during trading hours on Monday, hitting $56.96. 1,310,613 shares of the company’s stock were exchanged, compared to its average volume of 1,505,627. The company’s 50-day moving average price is $52.21 and its 200-day moving average price is $53.47. Vaxcyte, Inc. has a 1-year low of $29.08 and a 1-year high of $65.00. The stock has a market capitalization of $8.22 billion, a price-to-earnings ratio of -8.28 and a beta of 1.22.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($2.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.56). During the same quarter in the previous year, the company earned ($1.04) EPS. On average, research analysts expect that Vaxcyte, Inc. will post -7.91 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a research report on Wednesday, April 8th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Vaxcyte in a research note on Tuesday, March 10th. Finally, Wall Street Zen lowered Vaxcyte from a “sell” rating to a “strong sell” rating in a research note on Tuesday, April 28th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $86.00.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Smartleaf Asset Management LLC lifted its position in shares of Vaxcyte by 156.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock worth $27,000 after purchasing an additional 364 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its position in Vaxcyte by 1,463.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company’s stock worth $30,000 after purchasing an additional 600 shares during the last quarter. EverSource Wealth Advisors LLC raised its position in Vaxcyte by 33.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock worth $34,000 after purchasing an additional 184 shares during the last quarter. Allworth Financial LP lifted its holdings in Vaxcyte by 148.9% during the 3rd quarter. Allworth Financial LP now owns 1,222 shares of the company’s stock worth $44,000 after buying an additional 731 shares in the last quarter. Finally, CIBC Private Wealth Group LLC lifted its holdings in Vaxcyte by 22,500.0% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,356 shares of the company’s stock worth $49,000 after buying an additional 1,350 shares in the last quarter. 96.78% of the stock is owned by institutional investors.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.